RhumbLine Advisers
PRVL

RhumbLine Advisers’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

RhumbLine Advisers’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,258
Closed -$352K – 3054
2020
Q4 		$352K Buy
15,258
+1,050
+7% +$13.3K ﹤0.01% 2598
2020
Q3 		$145K Sell
14,208
-808
-5% -$10.8K ﹤0.01% 2783
2020
Q2 		$224K Buy
+15,016
New +$231K ﹤0.01% 2721

RhumbLine Advisers's PRVL Position: Q1 2021 in Review

RhumbLine Advisers sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 15,258 shares — an estimated $352K sold.

RhumbLine Advisers first reported a position in PRVL in Q2 2020 and held it in 3 quarters. The position peaked at $352K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • RhumbLine Advisers reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 15,258 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $352K.
  • RhumbLine Advisers first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • RhumbLine Advisers's Prevail Therapeutics Inc. Common Stock position peaked at $352K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.